Insider Trading Alert - JAZZ, THFF And OMN Traded By Insiders

Yesterday, Sept. 29, 2015, 45 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $447.15 to $2,831,587.72.

Highlighted Stocks Traded by Insiders:

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Miller Michael Patrick, who is SVP, US Commercial at Jazz Pharmaceuticals, sold 100 shares at $145.23 on Sept. 29, 2015. Following this transaction, the SVP, US Commercial owned 13,890 shares meaning that the stake was reduced by 0.71% with the 100-share transaction.

The shares most recently traded at $132.23, down $13.00, or 9.83% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,500
  • 12-Week # shares sold: 16,400
  • 24-Week # shares sold: 29,938

The average volume for Jazz Pharmaceuticals has been 476,000 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $8.3 billion and is part of the health care sector and drugs industry. Shares are down 23.77% year-to-date as of the close of trading on Tuesday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 29.1. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

First Financial Corporation (THFF) - FREE Research Report

Krieble William Randolph, who is Director at First Financial Corporation, bought 350 shares at $31.79 on Sept. 29, 2015. Following this transaction, the Director owned 4,452 shares meaning that the stake was boosted by 8.53% with the 350-share transaction.

The shares most recently traded at $32.43, up $0.64, or 1.97% since the insider transaction. Historical insider transactions for First Financial Corporation go as follows:

  • 4-Week # shares bought: 725
  • 12-Week # shares bought: 725
  • 24-Week # shares bought: 725

The average volume for First Financial Corporation has been 30,400 shares per day over the past 30 days. First Financial Corporation has a market cap of $414.7 million and is part of the financial sector and banking industry. Shares are down 9.6% year-to-date as of the close of trading on Tuesday.

First Financial Corporation, through its subsidiaries, provides various financial services. Its services include commercial, mortgage, and consumer lending; lease financing; trust account services; depositor services; and insurance services. The stock currently has a dividend yield of 3.03%. The company has a P/E ratio of 13.1. Currently, there are no analysts who rate First Financial Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on THFF - FREE

TheStreet Quant Ratings rates First Financial Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full First Financial Corporation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Omnova Solutions (OMN) - FREE Research Report

DeSantis Paul F, who is Sr VP Chief Financial Officer at Omnova Solutions, bought 2,000 shares at $5.10 on Sept. 29, 2015. Following this transaction, the Sr VP Chief Financial Officer owned 55,300 shares meaning that the stake was boosted by 3.75% with the 2,000-share transaction.

Esposito Frank P JR, who is Corporate Secretary at Omnova Solutions, bought 1,000 shares at $5.10 on Sept. 29, 2015. Following this transaction, the Corporate Secretary owned 3,500 shares meaning that the stake was boosted by 40% with the 1,000-share transaction.

The shares most recently traded at $5.52, up $0.42, or 7.61% since the insider transaction. Historical insider transactions for Omnova Solutions go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 39,105
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 39,105
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 39,105

The average volume for Omnova Solutions has been 111,300 shares per day over the past 30 days. Omnova Solutions has a market cap of $245.6 million and is part of the basic materials sector and chemicals industry. Shares are down 34.28% year-to-date as of the close of trading on Tuesday.

OMNOVA Solutions Inc. provides emulsion polymers, specialty chemicals, and engineered surfaces for various commercial, industrial, and residential end uses in North America, Europe, and Asia. The company operates in two segments, Performance Chemicals and Engineered Surfaces. The company has a P/E ratio of 45.7. Currently, there are 2 analysts who rate Omnova Solutions a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMN - FREE

TheStreet Quant Ratings rates Omnova Solutions as a hold. Among the primary strengths of the company is its generally strong cash flow from operations. At the same time, however, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Omnova Solutions Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks